Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
With development of its conditioning agent for leukemia patients undergoing stem cell transplants stalled due to significant dose-limiting toxicities seen in three clinical trial patients, Magenta Therapeutics, Inc. concluded its evaluation of strategic alternatives on 3 May by agreeing to a reverse merger with Dianthus Therapeutics